Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $1.6 million.

  • Tango Therapeutics' Change in Accured Expenses rose 19072.4% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 15200.55%. This contributed to the annual value of $1.1 million for FY2024, which is 15588.96% up from last year.
  • Latest data reveals that Tango Therapeutics reported Change in Accured Expenses of $1.6 million as of Q3 2025, which was up 19072.4% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Change in Accured Expenses peaked at $4.4 million during Q2 2022, and registered a low of -$6.7 million during Q1 2023.
  • Its 5-year average for Change in Accured Expenses is $377842.1, with a median of $1.1 million in 2025.
  • As far as peak fluctuations go, Tango Therapeutics' Change in Accured Expenses skyrocketed by 8802016.39% in 2021, and later plummeted by 416942.68% in 2023.
  • Quarter analysis of 5 years shows Tango Therapeutics' Change in Accured Expenses stood at $35000.0 in 2021, then soared by 4985.71% to $1.8 million in 2022, then soared by 124.55% to $4.0 million in 2023, then plummeted by 62.7% to $1.5 million in 2024, then rose by 7.58% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.1 million for Q2 2025, and -$6.1 million during Q1 2025.